Bioxyne Limited (AU:BXN) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxyne Limited has announced a change in director Anthony Ho’s interests, with the acquisition of 5 million unlisted options approved by shareholders. The options have an exercise price of $0.02 and expire in December 2027. This change aligns with the company’s strategic decisions and reflects shareholder support.
For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.